Personalized therapies for Crohn's and ulcerative colitis may follow from method that identifies harmful gut bacteria

Researchers have developed a new method to identify and target specific gut bacteria that contribute to inflammatory bowel diseases like Crohn's and ulcerative colitis. By using germ-free mice and patient stool samples, the team aims to enable more personalized medical treatments.
Why it matters
This discovery could lead to targeted therapies that treat the root cause of gut inflammation rather than just managing symptoms.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Bianca Hermle Patient microbiome inflammatory potential is recapitulated in Muc2-deficient mice. Credit: Gut (2026). DOI: 10.1136/gutjnl-2026-339262 Which gut bacteria contribute to the development or worsening of chronic inflammation? An international research team led by Dr. Lukas Mager from University Hospital Tübingen and Prof. Kathy McCoy from the University of Calgary has developed an approach to identify and selectively target such bacteria. The researchers identified two bacterial species that promote intestinal inflammation and compounds that selectively inhibit their growth. Published in the journal Gut , the study could pave the way for personalized therapies for inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in